Stem Cell Transplant

STEM CELL TRANSPLANT NEWS TIPS & FEATURES

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma

October 12th, 2016

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in younger patients with newly diagnosed multiple myeloma (MM). The findings of this trial clearly demonstrated that ASCT should remain the preferred treatment for younger patients with MM. The clinical trial […]


Ask the Expert: Multiple Myeloma

May 4th, 2016

Ask the Expert: Multiple Myeloma

CancerConnect recently collaborated with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) to provide you with the opportunity to engage with a multiple myeloma expert, Craig Hofmeister, MD, MPH. On April 28, 2016, Dr. Hofmeister guest-moderated on CancerConnect for a question-and-answer session in the Multiple […]


Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant

March 30th, 2016

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio is the first approved treatment for severe hepatic VOD. Hepatic VOD is a rare, but life-threatening complication that can occur following chemotherapy and a stem cell transplant (SCT) […]


Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant

December 30th, 2015

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose myeloablative treatment regimens were utilized since they were thought necessary to eradicate the malignant cells in the bone marrow. In recent years, SCT physicians have increasingly used reduced […]


December 28th, 2015

Data Back Stem Cell Transplant as Cure for Sickle Cell

A recent report suggests that over 90% of patients with sickle cell disease treated with an HLA-matched sibling stem-cell transplant (SCT) survive, free of disease, 3 years after treatment and are probably cured. The report summarized the results of 1,000 patients who underwent HLA-matched sibling transplants for sickle cell disease from 1986 through 2013, and […]


Prospective Study Shows Age Doesn’t Affect Survival Outcomes in Patients with Myelodysplastic Syndrome (MDS) Who Receive a Hematopoietic Cell Transplant (HCT)

December 14th, 2015

Prospective Study Shows Age Doesn’t Affect Survival Outcomes in Patients with Myelodysplastic Syndrome (MDS) Who Receive a Hematopoietic Cell Transplant (HCT)

Results from a prospective study of 1,280 patients with myelodysplastic syndrome (MDS) showed that survival at 100 days and at two years following hematopoietic cell transplant (HCT) for patients aged 65 and older is comparable to patients aged 55 to 64. The study demonstrates that age alone should not be a determinant when considering HCT […]


July 30th, 2015

Promising Survival for AML Patients Treated with Stem Cells from Related Half Matched Donor

Patients with acute myeloid leukemia (AML) may have a promising new treatment option. Research shows that stem cell transplant from a “half matched” related donor plus chemotherapy results in similar survival as a transplant from an unrelated matched donor. Further more, transplant from a half matched donor lowers the risk of graft-versus-host disease (GVHD). These […]


Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma

May 7th, 2015

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with  Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these findings online. Hodgkin’s lymphoma is a cancer of the lymph system. It typically begins in the lymph nodes in one region of the body and then spreads throughout the […]


April 1st, 2015

International Marrow Donor Registries Reach 25 Million Potential Donors, Give Hope to Searching Blood Cancer Patients Around the World

CancerConnect News: This week, Bone Marrow Donors Worldwide (BMDW) and the World Marrow Donor Association (WMDA) announced that a record 25 million people worldwide are currently listed as potential volunteer marrow donors in hopes of saving the lives of those battling life-threatening blood cancers and diseases. The significant milestone gives greater hope to searching patients, caregivers […]


Phase II Clinical Trial Shows Stem Cell Transplantation Effective For Severe Multiple Sclerosis Treatment

February 26th, 2015

Phase II Clinical Trial Shows Stem Cell Transplantation Effective For Severe Multiple Sclerosis Treatment

A study published in the journal Neurology reveals that stem cell transplantation could be a more effective therapy in severe cases of multiple sclerosis (MS) than the drug mitoxantrone. The study is entitled “Autologous hematopoietic stem cell transplantation in multiple sclerosis.” MS is an immune-mediated disorder in which the body’s own immune system attacks the […]


More News →